RIRaúl Ibarra-Salce

Raúl Ibarra-Salce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Raúl Ibarra-Salce has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Manuel Ramón García-Sáenz

    Servicio de Endocrinología, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico

    2 shared publications
  • Abraham Mercado-Cherem

    Endocrinology Service and Research Unit in Endocrine Diseases, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, México City, Mexico

    1 shared publication
  • Aldo Ferreira-Hermosillo

    Unidad de Investigación Médica en Enfermedades Endocrinas Centro Médico Nacional Siglo XXI IMSS Ciudad de México 7 Servicio de Endocrinología

    1 shared publication
  • Aldo Ferreira-Hermosillo

    Unidad de Investigación Médica en Enfermedades Endócrinas, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico

    1 shared publication
  • Alma Vergara-Lopez

    Department of Endocrinology, CMN "20 de Noviembre", Institute for Social Security and Services for State Workers, México City 03229

    1 shared publication
  • Ana C. Cepeda-Nieto

    Facultad de Medicina Departamento de Investigación Universidad Autónoma de Coahuila Unidad Saltillo Coah.

    1 shared publication

Latest Publications

  • Open Access

    Extracellular Vesicle-Associated microRNAs as Candidate Biomarkers and Mediators of Diabetic Complications: Clinical and Translational Evidence Across Neuropathy, Diabetic Kidney Disease, Retinopathy, and MASLD

    by Raúl Ibarra-Salce, José Luis Eduardo Doval-Caballero, Daniel Uribe-Cortés, Genesis Dinora Eugenio-Ponce, Mariela Ibarra-Salce, Omar Jaime-Leal, Manuel Ramón García-Sáenz

    Background/Objectives: Type 2 diabetes is increasingly recognized as a systemic disorder driven not only by chronic hyperglycemia and insulin resistance, but also by dysregulated interorgan communication. Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as biologically active carriers of proteins, lipids, and microRNAs capable of modulating gene expression in recipient cells. This narrative review integrates clinical, experimental, and translational evidence on EV-associated microRNAs as candidate biomarkers and potential mediators of diabetic complications, with emphasis on diabetic neuropathy, diabetic kidney disease, diabetic retinopathy, and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This review was aligned with the SANRA framework and focused on biological plausibility, evidence from tissue and biofluids, biomarker potential, therapeutic implications, and barriers to clinical translation. Studies were additionally interpreted according to biological matrix, EV-carrier specificity, analytical platform, study design, and level of functional validation. Results: Across complications, EV-associated microRNAs appear to participate in shared pathogenic processes, including oxidative stress, inflammation, endothelial dysfunction, fibrosis, angiogenesis, neurodegeneration, and metabolic memory. In diabetic neuropathy, microRNAs such as miR-146a, miR-155, miR-21-5p, and miR-148a-3p have been linked to neuroinflammation, Schwann-cell dysfunction, axonal injury, and neuropathic pain. In diabetic kidney disease, miR-21, miR-29, miR-30, and miR-126 are implicated in podocyte injury, tubulointerstitial fibrosis, albuminuria, and microvascular dysfunction. In diabetic retinopathy, microRNAs including miR-146a, miR-155, miR-21, miR-126, and miR-200b contribute to neurovascular injury, inflammation, barrier disruption, and angiogenesis. In MASLD associated with diabetes, hepatocyte-derived EVs carrying microRNAs such as miR-1 and miR-126a-3p may link hepatic lipotoxicity to endothelial inflammatory and β-cell dysfunction. Conclusions: Although EV-associated microRNAs offer promising opportunities for biomarker discovery, risk stratification, and targeted therapies, clinical translation remains limited by heterogeneity in EV isolation, microRNA quantification, biological matrices, and outcome definitions. Distinguishing EV-associated miRNAs from total circulating extracellular miRNAs remains essential for biological interpretation. Standardized, longitudinal, and externally validated studies are required before these signals can be implemented as actionable tools in precision diabetes care.


  • Open Access

    Prueba de supresión valsartán-dexametasonacaptopril: especificidad en aldosteronismo primario

    by Raúl Ibarra-Salce, Manuel R. García-Sáenz, Andrea P. Tenorio-Rojo, Mario A. Santana-Mata, Susana P. Flores-Villagomez, Aldo Ferreira-Hermosillo, Luis E. Vega-Carrillo, Ana C. Cepeda-Nieto

    Antecedentes: El aldosteronismo primario (AP) es la causa más frecuente de hipertensión secundaria y es constantemente infradiagnosticado. La prueba de supresión valsartán-dexametasona- captopril (VDCST) es una prueba que posee buen rendimiento diagnóstico. Objetivo: Validar en población mexicana la VDCST para el diagnóstico de AP. Método: Estudio prospectivo de prueba diagnóstica. Comparación entre la VDCST y la relación aldosterona-renina (PAC/PRC) en combinación con aldosterona urinaria de 24 horas con carga oral de sodio. Resultados: Tres de 27 pacientes fueron diagnosticados. El área bajo la curva para la aldosterona post VDCST fue de 0.986 (p = 0.007, IC 95%: 0.945-1.00), y para el PAC/PRC post-VDCST de 0.972 (p = 0.009, IC 95%: 0.911-1.000). Aldosterona post-VDCST y PAC/PRC post- VDCST alcanzó sensibilidad del 100% y especificidad del 88% con valores de corte de 5.1 ng/dL y 0.88 ng/dL/mUI/L, respectivamente. Conclusiones: PAC/PRC puede infradiagnosticar el AP. La VDCST cuenta con buen rendimiento diagnóstico de AP. La renina estimulada puede diferenciar pacientes con AP que se muestran negativos con otras pruebas.

  • Open Access

    Understanding Progestins: From Basics to Clinical Applicability

    by Manuel García-Sáenz, Raúl Ibarra-Salce, Francisco Javier Pozos-Varela, Tania Sofia Mena-Ureta, Susana Flores-Villagómez, Mario Santana-Mata, Ramón G. De Los Santos-Aguilar, Daniel Uribe-Cortés, Aldo Ferreira-Hermosillo

    Progestin is a term used to describe a synthetic progestogen. The activity and potency of synthetic progestins are mostly evaluated via parameters associated with their endometrial effects, which are related to their interactions with progesterone, estrogen, androgen, glucocorticoid, and mineralocorticoid receptors. The chemical structure of progestins is the key to understanding their interactions with these receptors and predicting the other effects associated with these drugs. Due to their endometrial effect, progestins are used for different gynecological conditions, such as endometriosis, contraception, hormonal replacement therapy, and artificial reproduction techniques. This review is focused on improving our knowledge of progestins (from their history and biochemical effects related to their chemical structures to clinical applications in gynecological conditions) in order to improve clinical practice.


  • Correlation Between Hemoglobin Glycation Index Measured by Continuous Glucose Monitoring With Complications in Type 1 Diabetes

    by Raul Ibarra-Salce, Francisco Javier Pozos-Varela, Nestor Martinez-Zavala, Cesar Ernesto Lam-Chung, Tania Sofia Mena-Ureta, Marcela Janka-Zires, Raquel N. Faradji, Juan Ramon Madrigal-Sanroman, Natalia Eloisa de la Garza-Hernandez, Paloma Almeda-Valdes


  • Open Access

    Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry

    by Moisés Mercado, Coralys Abreu, Alma Vergara-López, Baldomero González-Virla, Ana-Laura Espinosa-De-Los-Monteros, Ernesto Sosa-Eroza, Diego Cadena-Obando, Daniel Cuevas-Ramos, Lesly A Portocarrero-Ortiz, Sara-Patricia Pérez-Reyes, et al.

    Context: Acromegaly registries constitute a valuable source of therapeutic outcome information in real-life. Objective: The objective of this work is to analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Design and Methods: Data were extracted from the MAR informatic platform. Surgical remission was defined by a postoperative postglucose (GH) of less than 1 ng/mL and an insulin-like growth factor 1 (IGF-1) of less than 1.2 × upper limit of normal (ULN). Pharmacological remission was defined by a basal GH of less than 1 ng/mL and an IGF-1 of less than 1.2 × ULN. Results: A total of 650 surgical outcomes were analyzed (94.6% transsphenoidal). Surgical remission was achieved in 40.15%, whereas 44.15% remained biochemically active. Persistently active disease after surgery was significantly associated with harboring an invasive macroadenoma, a basal GH of greater than 10 ng/mL, and/or an IGF-1 of greater than 2 × ULN at diagnosis on bivariate and multivariate analysis. The outcome of monotherapy with first-generation somatostatin analogs (SSAs) was evaluated in 267 patients (adjunctive in 65%), of whom 28.4% achieved remission. Persistently active disease was significantly associated with harboring an invasive macroadenoma as well as with pretreatment basal GH and IGF-1 levels of greater than 10 ng/mL and greater than 2 × ULN, respectively, on bivariate and multivariate analysis. Combined therapy with SSA and cabergoline was analyzed in 100 patients, of whom 19% achieved remission and 44% remained active; in this subset of patients, only a pretreatment IGF-1 of greater than 2 × ULN was significantly associated with persistent disease activity. Conclusion: Surgical and pharmacological outcomes in acromegaly are highly dependent on tumor size/invasiveness as well as on the degree of hypersomatotropinemia.